DK3542798T3 - Aceclidin til brug ved behandling af presbyopi - Google Patents

Aceclidin til brug ved behandling af presbyopi Download PDF

Info

Publication number
DK3542798T3
DK3542798T3 DK19171214.0T DK19171214T DK3542798T3 DK 3542798 T3 DK3542798 T3 DK 3542798T3 DK 19171214 T DK19171214 T DK 19171214T DK 3542798 T3 DK3542798 T3 DK 3542798T3
Authority
DK
Denmark
Prior art keywords
aceclidine
presbyopia
treatment
Prior art date
Application number
DK19171214.0T
Other languages
Danish (da)
English (en)
Inventor
Gerald Horn
Lee Nordan
Original Assignee
Lenz Therapeutics Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lenz Therapeutics Operations Inc filed Critical Lenz Therapeutics Operations Inc
Application granted granted Critical
Publication of DK3542798T3 publication Critical patent/DK3542798T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK19171214.0T 2013-08-28 2014-08-22 Aceclidin til brug ved behandling af presbyopi DK3542798T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361871215P 2013-08-28 2013-08-28
US201361882998P 2013-09-26 2013-09-26
US201361904510P 2013-11-15 2013-11-15
US201361917620P 2013-12-18 2013-12-18
US201461938438P 2014-02-11 2014-02-11
EP14840282.9A EP3038610A4 (en) 2013-08-28 2014-08-22 Compositions and methods for the treatment of presbyopia

Publications (1)

Publication Number Publication Date
DK3542798T3 true DK3542798T3 (da) 2025-05-19

Family

ID=52584080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19171214.0T DK3542798T3 (da) 2013-08-28 2014-08-22 Aceclidin til brug ved behandling af presbyopi

Country Status (22)

Country Link
US (1) US9089562B2 (https=)
EP (3) EP3542798B1 (https=)
JP (6) JP6426743B2 (https=)
KR (4) KR20160045147A (https=)
CN (1) CN105792815B (https=)
AU (2) AU2014311558B2 (https=)
CA (1) CA2922802C (https=)
DK (1) DK3542798T3 (https=)
ES (1) ES3028364T3 (https=)
FI (1) FI3542798T3 (https=)
HK (1) HK1225654A1 (https=)
HR (1) HRP20250507T1 (https=)
HU (1) HUE071646T2 (https=)
LT (1) LT3542798T (https=)
MX (2) MX393360B (https=)
PL (1) PL3542798T3 (https=)
PT (1) PT3542798T (https=)
RS (1) RS66821B1 (https=)
SG (1) SG11201601412XA (https=)
SI (1) SI3542798T1 (https=)
SM (1) SMT202500311T1 (https=)
WO (1) WO2015031186A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113525C2 (xx) 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN106455567A (zh) * 2013-12-18 2017-02-22 Gnt有限责任公司 用于治疗青光眼的组合物和方法
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2016205071A1 (en) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
KR20180014825A (ko) * 2015-06-18 2018-02-09 프레스바이오피아 세라피스, 엘엘씨 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법
CN106526888B (zh) * 2015-09-15 2019-08-06 星欧光学股份有限公司 隐形眼镜产品
US10845622B2 (en) 2015-09-15 2020-11-24 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
US12298602B2 (en) 2015-09-15 2025-05-13 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
PT3500255T (pt) * 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
IT201700069664A1 (it) * 2017-06-22 2018-12-22 For Health Pharma S R L Nuova formulazione oftalmica a base di tropicamide
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
CA3070556A1 (en) * 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
JP6603785B2 (ja) * 2017-12-08 2019-11-06 千寿製薬株式会社 水溶性高分子を含む水性液剤
PL3681500T3 (pl) 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途
JP2020033290A (ja) * 2018-08-29 2020-03-05 興和株式会社 水性組成物
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
US10836760B2 (en) 2018-10-10 2020-11-17 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
WO2020252057A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
CN114502155A (zh) * 2019-06-10 2022-05-13 视觉治疗股份有限公司 增强抗老视作用的卡巴胆碱-溴莫尼定制剂
CA3147107A1 (en) * 2019-07-26 2021-02-04 Allergan, Inc. Compositions and methods for treatment of presbyopia
WO2021236671A1 (en) * 2020-05-18 2021-11-25 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
US20230190738A1 (en) * 2021-12-16 2023-06-22 Lenz Therapeutics, Inc. Compositions and methods for the treatment of eye conditions
PL4312986T3 (pl) * 2021-04-01 2025-02-17 Active Biotech Ab Preparat lakwinimodu do stosowania do oczu
WO2022232205A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. A method of reducing brow ache
KR102415950B1 (ko) 2021-07-13 2022-07-05 백두하 백국화 추출물, 모과 추출물 및 용안육 추출물의 혼합물을 유효성분으로 포함하는 눈 건강 기능 식품 및 이의 제조방법
TW202333662A (zh) * 2021-11-10 2023-09-01 美商偉視醫療股份有限公司 增強抗老花眼效果之卡巴可(carbachol)調配物
WO2023091439A1 (en) * 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
CN114588156B (zh) * 2022-04-22 2024-06-11 温州医科大学附属眼视光医院 一种眼用制剂及其在治疗老花眼中的应用
KR102678138B1 (ko) * 2022-09-29 2024-06-25 주식회사태준제약 브리모니딘을 포함하는 안과용 조성물
KR20240099055A (ko) * 2022-12-21 2024-06-28 주식회사 대웅테라퓨틱스 이나보글리플로진을 포함하는 점안제 형태의 약학 조성물
WO2024220441A1 (en) * 2023-04-17 2024-10-24 Lenz Therapeutics Operations, Inc. Methods for the treatment of presbyopia
CN119789854A (zh) * 2023-08-04 2025-04-08 Ads医疗有限责任公司 用于递送眼科活性物的组合物和方法
CN119700989A (zh) * 2023-09-28 2025-03-28 苏州普乐康医药科技有限公司 一种α-肾上腺素受体激动剂眼用组合物及其用途
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
JP2003201241A (ja) 2001-10-22 2003-07-18 Rohto Pharmaceut Co Ltd 眼科用組成物
JP2004168709A (ja) * 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008536866A (ja) 2005-04-15 2008-09-11 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ アミン作動性医薬組成物および方法
ES2329161T3 (es) 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
EP2097044A4 (en) * 2006-12-26 2012-10-10 Quadra Logic Tech Inc DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20110212142A1 (en) * 2008-11-17 2011-09-01 Laila Pharmaceuticals Pvt.Ltd. Curcuminoids and its metabolites for the application in ocular diseases
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
AU2009347921B8 (en) 2009-06-10 2014-07-24 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
WO2011011519A1 (en) * 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
JP2013523825A (ja) * 2010-04-07 2013-06-17 アラーガン インコーポレイテッド 眼科製剤のための保存剤組成物の組み合わせ
WO2011127151A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
JP2014506936A (ja) 2011-03-03 2014-03-20 アラーガン インコーポレイテッド シリコーンベースの眼科製剤
UA113525C2 (xx) 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
CA2922802A1 (en) 2015-03-05
ES3028364T3 (en) 2025-06-19
EP3542798B1 (en) 2025-03-19
PT3542798T (pt) 2025-05-20
AU2019200623B2 (en) 2019-10-03
LT3542798T (lt) 2025-06-10
KR20220129097A (ko) 2022-09-22
AU2019200623A1 (en) 2019-02-21
SG11201601412XA (en) 2016-03-30
JP2021183634A (ja) 2021-12-02
WO2015031186A1 (en) 2015-03-05
EP3038610A1 (en) 2016-07-06
AU2014311558A1 (en) 2016-03-17
JP7358221B2 (ja) 2023-10-10
KR20160045147A (ko) 2016-04-26
JP2025131705A (ja) 2025-09-09
EP4563162A3 (en) 2025-08-20
JP7329019B2 (ja) 2023-08-17
US20150065511A1 (en) 2015-03-05
CA2922802C (en) 2021-04-27
MX393360B (es) 2025-03-24
MX2020002922A (es) 2020-07-22
AU2014311558B2 (en) 2019-01-24
RS66821B1 (sr) 2025-06-30
HUE071646T2 (hu) 2025-09-28
MX2016002623A (es) 2016-09-23
JP2016529297A (ja) 2016-09-23
KR20260008183A (ko) 2026-01-15
HRP20250507T1 (hr) 2025-06-20
KR20230157530A (ko) 2023-11-16
JP6426743B2 (ja) 2018-11-21
JP2019031538A (ja) 2019-02-28
PL3542798T3 (pl) 2025-09-08
SMT202500311T1 (it) 2025-09-12
HK1225654A1 (zh) 2017-09-15
US9089562B2 (en) 2015-07-28
KR102905081B1 (ko) 2025-12-26
CN105792815A (zh) 2016-07-20
EP3542798A1 (en) 2019-09-25
EP3038610A4 (en) 2017-03-22
JP2023103400A (ja) 2023-07-26
KR102600484B1 (ko) 2023-11-09
JP2020055851A (ja) 2020-04-09
CN105792815B (zh) 2018-08-28
SI3542798T1 (sl) 2025-07-31
EP4563162A2 (en) 2025-06-04
FI3542798T3 (fi) 2025-05-21

Similar Documents

Publication Publication Date Title
DK3542798T3 (da) Aceclidin til brug ved behandling af presbyopi
DK3167318T3 (da) Polarisationsuafhængig behandling ved integreret fotonik
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK2968208T3 (da) Behandling af kataplexi
DK3060237T3 (da) Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer
IL240388A0 (en) Methods of treating melanoma
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
LT2885010T (lt) Tautopatijos gydymo būdai
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
LT3007726T (lt) Tautopatijos gydymo būdai
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3391902T5 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
EP2982331A4 (en) Treatment tool
DK3556383T5 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer
DK2964248T3 (da) Behandling af og profylakse for stråledermatitis
ITRM20120473A1 (it) Use of glycerophosphoinositols for the treatment of septic shock
DK2976101T3 (da) Behandlingsfremgangsmåde